ArticleThe pharmacogenomics journal2018
Pharmacogenomic survey of Qatari populations using whole-genome and exome sequences.
Article in The pharmacogenomics journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- Genetic Variation among Pharmacogenes in the Sardinian Population.International journal of molecular sciences · 2022Article
- Pharmacogenomic landscape of Indian population using whole genomes.Clinical and translational science · 2022Article
- Pharmacogenomic analysis of a genetically distinct Indigenous population.The pharmacogenomics journal · 2022Article
- A population study of clinically actionable genetic variation affecting drug response from the Middle East.NPJ genomic medicine · 2022Article
- Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population.PloS one · 2022Article
- PharmVIP: A Web-Based Tool for Pharmacogenomic Variant Analysis and Interpretation.Journal of personalized medicine · 2021Article
- A Study on the Genetics of Primary Ciliary Dyskinesia.Journal of clinical medicine · 2021Article
- Genetic Epidemiology of Medication Safety and Efficacy Related Variants in the Central Han Chinese Population With Whole Genome Sequencing.Frontiers in pharmacology · 2021Article
- Article
- Qatari Genotype May Contribute to Complications in Type 2 Diabetes.Journal of diabetes research · 2020Article
- MTHFR and F5 genetic variations have association with preeclampsia in Pakistani patients: a case control study.BMC medical genetics · 2019Article
- Genomics of rare genetic diseases-experiences from India.Human genomics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Arabs represent one of the most genetically heterogeneous populations characterized by a high prevalence of Mendelian disorders due to consanguinity. Population-scale genomic datasets provide a unique opportunity to understand the epidemiology of variants associated with differential therapeutic response. We analyzed publicly available genomic data for 1005 Qatari individuals encompassing five subpopulations. The frequencies of known and novel pharmacogenetic variants were compared with global populations. Impact of genetic substructure on the pharmacogenetic landscape of the population was studied. We report an average of three clinically actionable pharmacogenetic variants with FDA-recommended genetic testing per Qatari individual regardless of their genetic ancestry. We observed extensive differences in the frequencies of clinically actionable pharmacogenetic variants among the Qatari subpopulations. Our analysis revealed 3579 deleterious pharmacogenetic variants potentially altering the function of 1163 genes associated with 1565 drugs. This study has thus compiled the first comprehensive landscape of pharmacogenetic variants for any Arab population.
Indexed as
Identifiers
29720721What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.